Hydrastis canadensis - Goldenseal
Goldenseal
Hydrastis canadensis
Chad Bradshaw
General Description
- Cultivated in North America’s wooded areas (New York, Missouri, Oregon, Washington, Western Ontario)
- Knotty, yellow, small perennial plant
- Harvested for rhizome and root
- Early spring, 2 round leaves ending in a single green-white flower
Chemical Composition
- Active component: berberine (alkaloid) 0.5 - 6.0%
- Other components:
- berberastine (2-3%)
- canadine
- hydrastine (1.5-4%)
- meconin
- chlorogenic acid
- phytosterins and resins
History and Folk Use
- Used by Native Americans
- Clothes dye
- Inflammatory mucous membranes
- Ocular disorders
- Ulcers
- Arrow wounds
- War paint for face
Pharmacology of Berberine
- Antibiotic
- Immunostimulatory
- Anticonvulsant
- Sedative
Antibiotic Activity
Active against:
- Staphylococcus species
- Streptomyces species
- Chlamydia species
- Corynebacterium diptheria
- E. coli
- Salmonella typhi
- Vibrio Cholerae
- Diplococcus pneumoniae
- Pseudomonas species
Efficacy as an Antimicrobial
- Inhibition of Candida and pathogenic bacteria prevents the overgrowth of yeast (a common side effect of antibiotic use)
- Inhibits adhesion of streptococci to host cells:
- Causes streptococci to lose lipoteichoic acid, which is responsible for adherence of the bacteria to host tissues
- Prevents adhesion of fibronectin to streptococci
Other Actions
- Immunostimulatory
- Increases blood supply to spleen, which may promote optimal splenic activity
- Activates macrophages
- Fever-reducing
- Appears to do this by enhancing immune system’s ability to handle pyrogenic organisms
- Rat model: 3 x antipyretic effect of aspirin
- Anticancer Effects*
- Directly kills tumor cells
- Indirectly kills tumor cells by stimulating white blood cells
- In vitro studies showed average cell kill rate of 91%, over twice that of BCNU (standard chemo agent for brain tumors)
- Rat studies showed 81% kill rate with 10 mg/kg berberine
- Combination with BCNU may be very effective
Clinical Applications
- Infectious diarrhea*
- Trachoma (ocular infection found in underdeveloped countries)*
- Liver Disorders*
- Stimulates secretion of bile and bilirubin
- Cancer*
Daily Dosage:
Based on Berberine content
- Dried root/Infusion: 2-4 grams
- Tincture (1:5): 6-12 mL
- Fluid Extract (1:1): 2-4 mL
- Solid extract (4:1 or 8-12% alkaloid content): 250 - 500 mg
- Mouthwash: 2 tsp (6g) herb + 1 cup water; use TID-QID
- Externally: 1 tsp root + 1 pint water; use as lotion
Toxicity
- Generally nontoxic at recommended dosages
- Not recommended for use during pregnancy because it stimulates the uterus and may produce abortion or premature labor
- Eating fresh plant may produce ulcerations and inflammation of mucosal tissue
- Long-term use may weaken colonic bacterial flora
Clinical Trials:
Clinical Trial 1: Clinical Trial of Berberine in Acute Watery Diarrhea
Methods:
- Randomized, placebo-controlled, double-blind
- Compared berberine(100mg qid), tetracycline (500 mg qid), and both agents concurrently.
- Patients with cholera and treated with tetracycline or tetracycline + berberine had less volume and frequency of diarrheal stools, shorter duration or diarrhea, and smaller required volumes of fluid for rehydration.
Results:
- Cholera patients treated with berberine alone excreted more Vibria Cholerae after 24 hours of treatment than patients treated with tetracycline with or w/o berberine
- Neither agent had any benefit over placebo in non-cholera diarrhea.
- Researchers postulate that the dose of Berberine may have been subtherapeutic.
Clinical Trial 2: Clinical Trial of High-Dose Berberine and Tetracycline in Cholera
- Follow-up to previous trial, researched and reported by the same authors.
- Compared effectiveness of tetracycline with and without berberine
- Dosage increased to 200 mg berberine (100 mg in previous trial)
- Found no significant difference in stool volume, # of motions, or duration of diarrhea..
Clinical Trial 3: Randomized Controlled Trial of Berberine Sulfate Therapy for Diarrhea Due to Enterotoxigenic Escherichia coli and Vibrio Cholerae
- Patients infected with E. Coli received a single dose of either 400 mg berberine or 100 mL of water (control).
- Mean stool volumes in treated patients were significantly less than those of the controls.
- Diarrhea stopped in 42% of treated patients.
- Patients infected with cholera received either:
- 400 mg berberine single dose
- 1,200 mg berberine (400 mg q 8 h x 24 h) + 1 g tetracycline po single dose
- 1 g tetracycline alone
- Placebo
- Patients who received a single 400 mg dose of berberine had a mean 8-hour stool volume decrease from 2.79 L to 2.22 L.
- Patients treated with berberine 400 mg + tetracycline 1 g did not show a significant reduction in stool output compared to patients treated with tetracycline alone.
- Suggests that berberine antagonizes tetracycline.
- Results also suggest that berberine is effective and safe for diarrhea caused by E. Coli but is only slightly effective against cholera.
Clinical Trial 4: Effect of Berberine Chloride Eye Drops on Clinically Positive Trachoma Patients
- Trachoma: contagious disease of the conjunctive of the eye caused by Chlamydia Trachomatis; characterized by inflammation, hypertrophy, and granules of adenoid tissue.
- Major cause of blindness and impaired vision in underdeveloped countries.
Methods:
- Patients with active trachoma were given either:
- 0.2 % berberine eye drops
- Berberine (0.2%) + sulphacetamide (20%) drops
- Sulphacetamide (20%) eye drops
- Two drops TID in each eye for 3 weeks.
- Patients evaluated after 8 weeks.
Results:
- Patients treated with only berberine showed negative conjunctival scrapings, but infection disappeared gradually.
- Patients treated with berberine + sulphacetamide had best clinical improvement, but scrapings returned to positive, and all patients relapsed.
- Patients treated with only sulphacetamide also had positive scrapings, and some patients relapsed.
Conclusions:
- Suggests that berberine may be curative for trachoma, probably by stimulating host defenses.
- Study included no placebo group, and sample sizes were small.
Conclusions from Clinical Trials
- Berberine may be useful in GI infections caused by E. Coli, however it does not appear to be useful against Vibrio cholerae (cholera).
- Berberine may be useful in the treatment of trachoma.
References
Pizzorno & Murray. Hydrastis Canadensis, Berberis Vulgaris, Berberis Aquifolium, and other Berberine-Containing Plants. In: Textbook of Natural Medicine. Vol. 1. Washington: John Bastyr College Publications, 1985.
Goldenseal. In: Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York: Pharmaceutical Products Press, 1994.
Goldenseal. In: Weiner's Herbals: The Guide to Herb Medicine, California: Quantum Books, 1990.
Goldenseal. In: Alternative Medicine: The Definitive Guide. Puyallup, WA: Future Medicine Pub., 1994.
Goldenseal (Hydrastis Canadensis). The Alternative Health & Medicine Encylopedia. New York: Gale Research, Inc., 1995.
Babbar OP, Chhatwal VK, Ray IB, Mehra MK. Effect of berberine chloride eye drops on clinically positive trachoma patients. Indian J Med Res 1982 December; 76:pp 83-88.
Khin-Maung U, Myo-Khin, Nyunt-Nyunt-Wai, Aye Kyaw, Tin-U. Clinical trial of berberine in acute watery diarrhoea. BMJ 1985 Dec 7; 291: pp. 1601-1604.
Khin-Maung U, Myo-Khin, Nyunt-Nyunt-Wai, Aye Kyaw, Tin-U. Clinical Trial of High-Dose Berberine and Tetracycline in Cholera. J Diarrhoeal Dis Res 1987 Sep 5(3):184-187.
Mills, Simon Y. The Dictionary of Modern Herbalism. New York: MJF Books, 1988.
Murray, Michael T. The Healing Power of Herbs. California: Prima Publishing, 1995.
Murray, Michael T. et al. Naturopathy. Cothell, WA: John Bastyr College Publications, 1985.
Ritchason, Jack. The Little Herb Encyclopedia, 3rd Ed. Utah: Woodland Health Books, 1995.
Sollmann, T. A Manual of Pharmacology, 7th Ed. 1948.
http://www.egregore.com/herb/Goldenseal.htm
http://www.healthherbs.com/sing132.htm
http://www.pacific.net/~harnish/Goldenseal_Notes.html


Comments